Phase II trial of combined modality therapy with myeloid growth factor support in patients with locally advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 6, 2010, Pages 837-840

  Lilenbaum, Rogerio ^a   Samuels, Michael ^a   Taffaro Neskey, Michele ^a   Cusnir, Mike ^a   Pizzolato, Joseph ^a   Blaustein, Arnold ^a  

^a Mount Sinai Cancer Center   (United States)

Author keywords

Combined modality therapy; Myeloid growth factors; Stage III NSCLC

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; DOCETAXEL; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; FILGRASTIM; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHYSICAL PERFORMANCE; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; SIDE EFFECT; SURVIVAL RATE; THERAPY DELAY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT PROTEINS;

EID: 77953126777     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d6e141     Document Type: Article

References (9)

1. Pfister DG, Johnson DH, Azzoli CG, et al; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
2. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidencebased clinical practice guidelines. J Clin Oncol 2006;24:3187-3205.
3. Bunn PA, Crowley JC, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995;13:1632-1641.
4. Gandara K, Chansky KS, Albain, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small cell lung cancer: phase II Southwest Oncology Group Study 9504. J Clin Oncol 2003;21:2004-2010.
5. Hanna N, Neubauer M, Yiannoutsos C, et al. Cisplatin plus etoposide plus concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer: a randomized phase III study from the Hoosier Oncology Group and U. S. Oncology. J Clin Oncol 2008;26:5755-5760.
6. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456.
7. Gaspar LE, McCoy J, Kelly K, et al. Analysis of V20 and radiation pneumonitis on SWOG 0023: a phase II trial of concurrent chemoradiation and docetaxel consolidation in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2006;66 (suppl 1) : S61-S62.
8. Lieschke GJ, Burgess A. Granulocyte colonystimulating factor and granulocyte macrophage colony-stimulating factor. N Engl J Med 1992;327:28-35;99-106.
9. Govindan R, Bogart J, Vokes E. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol 2008;3:917-928.